European Commission Call for Proposals: Innovations to accelerate vaccine development and manufacture
European Commission opened a call from the action type IMI2-RIA Research Innovation action, on innovations to accelerate vaccine development and manufacture, with the overall objective to accelerate and de-risk the development of new vaccines by incorporating scientific and technological advances from the academic and biotech sectors into industry, and to develop more predictive biological and mathematical models of vaccine performance.
The topic is composed of four subtopics with the following specific objectives:
- to develop an open-data/open-source in silico platform focussed on immunobiological processes, and not on a given disease or vaccine indication.
- to develop improved or novel CHIMs for influenza, RSV and C. difficile, to facilitate the generation of early efficacy data for vaccine candidates.
- to develop (i) prototype next-generation in vitro systems for antigen identification/validation and drug substance and drug product characterisation/validation; and (ii) associated functional immune assays for clinically-relevant (surrogate) endpoints.
- to develop an open data/open source in silico biomanufacturing platform incorporating models for (i) predicting vaccine-product stability; and (ii) the parameters to maintain process robustness for unit-operation scale up or scale down, and for process transfer.
Read more here.
Proposals deadline May 12, 2020.
